|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE26
|
|
gptkbp:brand
|
gptkb:Cabometyx
gptkb:Cometriq
|
|
gptkbp:CASNumber
|
849217-68-1
|
|
gptkbp:chemicalFormula
|
C28H24FN3O5
|
|
gptkbp:contraindication
|
hypersensitivity to cabozantinib
|
|
gptkbp:developedBy
|
gptkb:Exelixis
|
|
gptkbp:discoveredBy
|
gptkb:Exelixis
|
|
gptkbp:drugClass
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
99 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cabozantinib
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Takeda
gptkb:Exelixis
gptkb:Ipsen
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
99.7%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
diarrhea
fatigue
hypertension
decreased appetite
|
|
gptkbp:target
|
gptkb:VEGFR
gptkb:KIT
gptkb:RET
gptkb:AXL
gptkb:TIE2
gptkb:MET
|
|
gptkbp:usedFor
|
hepatocellular carcinoma
renal cell carcinoma
medullary thyroid cancer
|
|
gptkbp:bfsParent
|
gptkb:RET
gptkb:RET_proto-oncogene
|
|
gptkbp:bfsLayer
|
5
|